<SEC-DOCUMENT>0001129928-13-000012.txt : 20130305
<SEC-HEADER>0001129928-13-000012.hdr.sgml : 20130305
<ACCEPTANCE-DATETIME>20130305122634
ACCESSION NUMBER:		0001129928-13-000012
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130305
FILED AS OF DATE:		20130305
DATE AS OF CHANGE:		20130305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		13664663

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of&#160;March 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-31062</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">News Release Dated March 5, 2013: Oncolytics Biotech&#174; Inc. Completes Patient Enrollment in U.S. Phase 2 Study of REOLYSIN&#174; in Non-Small Cell Lung Cancer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="4" valign="top" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date:&#160;&#160;March 5, 2013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/&#160;&#160;Kirk Look</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kirk Look</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>ex99.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>ex99.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><img src="onclogo.jpg" alt=""><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr. N.W.</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Calgary, Alberta</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR IMMEDIATE RELEASE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Inc. Completes Patient Enrollment in U.S. Phase 2 Study of REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> in Non-Small Cell Lung Cancer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, --- March 5, 2013</font> - Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221;) (TSX:ONC, NASDAQ:ONCY) today announced that it has completed patient enrollment in a Phase 2 clinical trial evaluating intravenous administration of REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with <font style="FONT-STYLE: italic; DISPLAY: inline">Kras</font> or EGFR-activated tumours (REO 016).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This trial is a single arm, single-stage, open-label, Phase 2 study of REOLYSIN given intravenously with paclitaxel and carboplatin every three weeks. Patients received four to six cycles of paclitaxel and carboplatin in conjunction with REOLYSIN, following which REOLYSIN could be continued as a monotherapy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Eligible patients included those with metastatic or recurrent NSCLC with <font style="FONT-STYLE: italic; DISPLAY: inline">Kras</font> or EGFR-activated tumours, who had not received chemotherapy treatment for their metastatic or recurrent disease. Patients must have demonstrated mutations in <font style="FONT-STYLE: italic; DISPLAY: inline">Kras</font> or EGFR, or EGFR gene amplification in their tumours (metastatic or primary) in order to qualify for the trial.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company previously reported in November 2012 that 33 patients had received Reovirus (REOLYSIN) (3 x 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">10</font> TCID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: sub">50</font>) intravenously daily on days one to five, in combination with carboplatin and paclitaxel. Molecular tumor demographics included: 16 <font style="FONT-STYLE: italic; DISPLAY: inline">Kras</font>, three EGFR, four BRAF mutations, and 10 EGFR amplified only. Response evaluation data reported among 30 evaluable patients showed 27 patients had stable disease or better for a 90% clinical benefit rate (nine partial response (PR) (30%) and 18 stable disease (SD) (60%)). Three patients had progressive disease (PD) as their best response.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We have seen encouraging results in both this and other trials looking at primary and metastatic lung disease and are continuing to push our lung program forward on that basis,&#8221; said Dr. Brad Thompson, President and CEO of Oncolytics.&#160;&#160;&#8220;We have extended our work in this indication beyond this drug combination and are currently evaluating REOLYSIN in conjunction with docetaxel or pemetrexed in a second line open-label, randomized, non-blinded, Phase II clinical study sponsored by the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario that will enroll up to 150 squamous cell and adenocarcinoma of the lung patients.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will or may occur in the future, including such things as, the Company's expectations related to the Phase 2 non-small cell lung cancer trial of REOLYSIN in combination with paclitaxel and carboplatin, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">and other such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements and forward-looking information. Such risks and uncertainties include, among others, risks related to the statistical sufficiency of patient enrollment numbers in separate patient groups, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statement and forward-looking information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by applicable laws.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Equicom Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nick Hurst</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW, 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta, T2P 3C4</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel: 403.218.2835</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax: 403.218.2830</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">nhurst@tmxequicom.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dian Griesel, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Susan Forman</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">396 West Broadway, 2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">New York, NY&#160;&#160;10012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel:&#160;&#160;212.825.3210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax:&#160;&#160;212.825.3229</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">sforman@dgicomm.com</font></font></div>
</td>
<td valign="top" width="28%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-30-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>onclogo.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 onclogo.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0E(17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````0````<@$R``(````4````@H=I``0````!````E@```+8```$L````
M`0```2P````!4&%I;G0N3D54('8U+C`P`#(P,#@Z,#4Z,C(@,34Z,CDZ,S@`
M``*@`@`$`````0```\"@`P`$`````0```.$`````````!@$#``,````!``8`
M``$:``4````!```!!`$;``4````!```!#`$H``,````!``(```(!``0````!
M```!%`("``0````!```(+`````````!(`````0```$@````!_]C_X``02D9)
M1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$
M``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,
M#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`"8`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"
M!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($
M`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&
M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/55C]2^
ML3,?,_9O3\=_4^I@!S\>DAK:VGZ+LS)?^BQMWYG^%_X-%^L?4KNF])MOQFA^
M786T8C#WNN<*:/\`->_U%/HG1Z.D8+<:LFVYY-F5DNU?=<[W77VN^DYSW)I)
M)H:=RIH[_KT[WBKI=0.OI.?>YP_DNM:QK/\`P-*GZRW8V37A]?PSTRVXAE&2
M'BW%L<>*VY(#/1M?^95D,8MY`S<+%S\6W#S*VW8][=ME;N"#_K[7)<)&Q/U4
MG26']5[\FMF7T7,L-V1TBT5-N=]*S'>WU<*VP_Z3TOT5G_%+<1!L6I2228D#
MG1%2Z22:1,=TE+I)))*4DDDDI22222E)))@0>-4E+I)BX")($\2G24__T.W^
MMWLIZ7>[2JCJ>*^UW8-+G5!SOZMEE:WE5ZIT['ZIT_(Z?DSZ60PL<1R#RRQO
M\NM_Z1BR>B]=LJM;T3KSA1U:D!M=KM*\M@]K,G&>[VNL?_AJ/YSU$W:1O])+
MT"22R>M?6#'Z<6XF.W[9U:_3%P*C+W']^W_08[?IV76_F(D@;H:_3"+/K;UI
M[/HUTX=3_.R+K?\`HUVUK*HQ.HGK?7.H=),9^+E,!Q["6U9-+J:G.Q7S[:K=
M_OQLK_!6?SGZ&Q=!]7^E6=,P7-R;!=G95CLG.N:(#KK/I[/^"K;MJJ_X-B:K
MK+[,_P"QG%>T>M91ZG,>FSU6W/9M]M-WT&6?03*T%Z:D_P",EH?5&]F3D]:R
M:V65-NS`[T[FEEC3Z-#;*[*W?1?7:U]:I=-_98R,P?6P5?M0WV;'9X'H^A/Z
MN.FNR?U;[/L^DVG]-ZG])]ZZG)R319C,%;K/M-OI%S>&#T[;O4?_`"/T/I_]
M<4<_+=B8_K-J=<2]C(;PT/<&>K:[W;**MWJ76;?T=:/#IO\`+X:*<SJ0>[ZJ
MY#?JN&L=Z3AB#'`9^=^E^S_1VV?SOI?\(L[_`+!3TN"RAEVSZ&V.H"R/W?\`
ME'[=ZG_7O4718.<[+?>PU%@H>&BUIW56`M;9NHMAGJ;-WIV^S^=3?:\G]I?8
M_0'I>GZOK[C$3LV;?3V^K_(]3Z"1`-'3]W93S^8WJCO\7%S>J!YSSAN%H?K9
MW]/U-O\`A?2V>I_PBV>F=9Z3>S'Q*,RFS(-;0*FO!<2UNY_M^E[6M1^I=0=@
MMH(I-WKV^D2#`8-EEWJ6.AWM_0^G_7L5JI_J5L?I[FAVAD:C\UVB(%'0[`#5
M3S'7,;)Z+E5Y?1+1C.ZSD,Q,FES/4J;==(KZI75+?3R*MOZ?_`Y?^&_2+8P.
MA=.PL!^#Z8R*[B7Y3\B+'WV.ULNRG/\`YU[W?^HT3IW479K0\UBC<W=Z+W'U
MF:QLR*-GZ&S]_P#2V(N5E.Q[,9C:7W?:+342R/8!7;?ZC]WMV?H?3_ZXD`-3
MT*GG>G=%Z/9]9NLX]F!COHJKQ#56ZEA8TO;=ZOI,<WTV[]OZ38K7UI'ZWT"!
MQU*O@<?H[_!;&!E.S,87NJ?02^QGIV:.'IO?3+OZ_I[U80$1PT.NO_=*>;^L
MF_\`:N`>HA[OJ^&O^TA@<:_7D>A^T&U>[['_`%_U;U?Z0KW2S]6/M3OV.,3[
M0:_>[$#/H`C1[Z!M^G^8KV/E&[(RJ36Y@QGM8'NX?NKKNWL_J^KZ?]A4^H]:
MLP+KV?8[KZZ:&W"VL%P+WFYM>/M:USO=Z'\[[_2]6OUO39[TM`>+]BGGLRGH
M[,_.O;G]-R;;+7.MHZO6'VL</8ZC&O=978S$;M_0U?9K_P#@UT'U9O%_1Z7M
MP?V:P%[68^H;M#C%M(<VJST;OYROU*JE=SLHX>*_(%3[RR/T=8EWN<&;O^+K
MW>I;_P`$I8MYOK+SZ9@Q^B?ZC?\`/V5I"-2W_!3_`/_1]56;U[]@_8'?M[T/
ML<_]J(C=_P`%^?ZO_%?I%\SI(2V.WUV4^Z,H^J3JM^-D]79A]JZAU'T8_D_H
MG>S^VMKZL_\`-3T[/^;_`*.^?T\3Z_\`Z$?:/UO_`+=7SBDHX[CY?I_W*?M?
MJI)?*J2E0_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+
MY5224_522^54DE/_V?_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN
M=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S4D="````
M``````````````#VU@`!`````-,M2%`@(```````````````````````````
M````````````````````````````````````$6-P<G0```%0````,V1E<V,`
M``&$````;'=T<'0```'P````%&)K<'0```($````%')865H```(8````%&=8
M65H```(L````%&)865H```)`````%&1M;F0```)4````<&1M9&0```+$````
MB'9U960```-,````AG9I97<```/4````)&QU;6D```/X````%&UE87,```0,
M````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\```(#&)44D,`
M``0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N,0``
M````````````$G-21T(@245#-C$Y-C8M,BXQ````````````````````````
M``````````````````````````````````````````!865H@````````\U$`
M`0````$6S%A96B``````````````````````6%E:(````````&^B```X]0``
M`Y!865H@````````8ID``+>%```8VEA96B`````````DH```#X0``+;/9&5S
M8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H```````````````6245#
M(&AT='`Z+R]W=W<N:65C+F-H````````````````````````````````````
M`````````````````````````&1E<V,`````````+DE%0R`V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````+DE%
M0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``
M``````````````````````````!D97-C`````````"Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ```````````````L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````
M````````````````````````````=FEE=P``````$Z3^`!1?+@`0SQ0``^W,
M``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S``````````$`
M```````````````````````"CP````)S:6<@`````$-25"!C=7)V````````
M!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`
M:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5
M`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!
M8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"`P(,
M`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"
MZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L
M`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%
M*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,
M!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+"!\(
M,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G[
M"A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,
M$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)
M#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0
MUQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C$T,38Q.#
M$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6
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MUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB
M/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R0K5"
M]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C7
M21U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/
M24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"
M5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<
MUETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K
M9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]K
MIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S`7-=
M<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[
MPGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=
MA("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-
M,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98T
MEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?
M^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFI
MJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,XLZZT
M);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$
MOO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)
MN<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;42=3+
MU4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@
MO>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&
M[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY
M./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`'`!X`,!(@`"$0$#
M$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#
M`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#
M`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!
M`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/[^
M****`"BBB@`HKA_B'\2/`_PH\+:IXX^(WBK0/!?A'18&N=4\0^)=5L]'TNSC
M7[JO=WLT,;W$[$0VEK%YES=W#QV]O#)+(JG\"/VE_P#@X"^%_A2YO_#G[,WP
MZO/B?J%N9;=/'GC>:Z\+>"S.&"BYTOP_%'_PE7B&SSM`%Z_A%YMP>T>=$#/X
M6;\29/D5/VF9XRE0;CS0HJ7/B*D=-8TE9Z7UU_,UI4:E:7+3BY6W?1']%]%?
MP^ZK_P`%._\`@J7^TKJMSI_PSU_QE"D[L/\`A%O@!\+4G:U$I!2*+4K#1_$?
MBZ*)0T:+)/KSW&X;?,>1Z?%X`_X+>:^HU(7'[>48G`<*_C_XE^'R%;)'_$NE
M\2:68?I]DB8?Q*,KGY!^)6&J^]E_#V?X^E_S^I83EAK:UM97OKVU5O3H^I27
MQ5:2[>]?M^5_N^X_M_HK^'.Z^(?_``6E^!*G5M9U#]L_3K*S'FSZCXMTCQG\
M0M"AB3.YKJ?Q)I_BC1VB`1FD-S*2%)9E"Q$CW#X+_P#!?']J;P%?6^E?'#P3
MX+^,&C6\GDZC-'IY^'7CA6#+',1>Z5!/X:<PXD86DOA.*:5T,,EVB%YDJAXG
M90JL:69Y?FN4.6]3%X9NE&UMW&U26ZNZ=*:5_>MI=_4*DOX=2E.V_O6MMZI]
M?N/['**_.C]DS_@J#^RO^UV]GH'A#Q3+X)^)-PBY^&/Q`^R:)XCN[@(6F3P[
M=+<SZ+XK1"DC"/1-0GU2.V47%]I=B"R+^B]??8#,<%F>'ABL!B:6*P\_AJT9
M<T7^3^](Y)PE3DX33C);IA111780%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%?$W[;7[<GPF_8C^&8\9^/9O
M[9\5:VEW:_#[X<Z7=0QZ_P",M7@1`^QG60:9H&G&:&;6]?N(9+>QB:.WMXK[
M5KK3],O/;?VA_CSX'_9H^$'C;XT?$6[^S>%_!6CS7\L$+QC4-8U.1DMM%\.Z
M3%(52;5=>U.>VTVQ1F6))IQ-</%:Q331_P`57@_PS^T/_P`%?OVS+^^U74)[
M&#4)EU#Q'K)2XNO"_P`&_A597VVRTC2H'>-6GCAF.G:/8;H+CQ+XBN;C6=3>
M,SZWJ4/PW%_%%?*5A<LRFC]<SW,Y^RPE"/O>P3Y;8BK&VRYO<BW%2M)\RL=>
M$H1K2G.II2I1YY^>NBW5KOK9^A)K'B#]N3_@K]\<O[.L8;S7-/TV[-S:Z#97
M%SHGP;^#VAW4\D$=UJ%PYFM8+GR&D1]2NAJ?BWQ"\,\%BMT%AL(/Z!_V3?\`
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M;6L**JJH6.)<`=3VZ"BBOT"G"-.*A",(16T814(KTBM$<(5\K?'G]BG]F+]I
M?3[JT^,'PA\(>)=0N$D2/Q5;:<FA^-;%GSB:R\7:(;#7HVC<^:()KZ:RF<!;
MNUN8=T3?5-%9XC"X?%P=+$T*.(IO>G6I4ZL7L]IQE;;I;S*4I1^%M>A_'G^V
MQ_P1'^*OP(BOOBK^RUK.O_%?P/H[G5KCPBZB+XL^$(K63[6+_2'TE;6'QC;Z
M>88Y_/TFWT_Q)`(T:#1=0%JUV/6?^":__!9G7/#.IZ'\!?VQM<GU3P]/<6^@
M^$OC1K#,-9\,7:SBU@TCXF2R+YVJ:.96%JGBV=?[5T615/B-KRQ%UJ^E?U9U
M_.;_`,%=O^"6.D^.]#\2?M2?L[>'H['XCZ3;WOB#XK>`=%M&6W\?Z7;0M-J/
MB[0-/MQY</C/355KS5[&WB8>++);RYC@F\3`_P!N?F&<<,8WAFN\_P"$)SIJ
MG=X_)K.>&Q5#3G=.G=*\%=VMI?38]"CB(XA1P^*]Y.RA5O:<'=7MH][1O?LK
MG]%%G>6]_;PW=K+#<6US#%<6UQ;RK/;W%O.N^">"9/W<L4T166.2,M')&ZNC
M,C!C:K^8O_@B+_P4,O=1FL?V,OC%K4E[>16D\GP)\2ZM=%[B6TTZVDN+WX97
MMY.3).]E903:AX->9G=+&VO]`1UBM-`LJ_ITK[KA[/L)Q%EE',L+[JG>G7HM
MWEA\1!+VE&3LKN+:M*RYK['%6I2HU)0ETUB_YH/X9>5UZA1117N&04444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%4M1U"UT
MNRN]0O9DM[2QM;F\NIY#A(;:TA>>>9SCA(XD9W/8#N>*&[)OMJ!_)1_P7N_:
MGO?&WQ;\)?LI>%[^:7PY\,(-/\6^.[6TD<KJOQ#\36(DT'2YXXR?M`\.>$]0
MMKBW5-V;[Q9<0E!/IL;)^XG_``3"_8YT_P#9!_9F\.:)J>G0Q?%;XA6VG^./
MBOJ+Q1_:TUO4+19M-\)^;R_V'P7I\XTB.'>T#ZK_`&QJ,(5-1"K_`"_?L7Z+
M=_MR?\%3]%\9^*H#J.CZ_P#%WQC\=_$T%WNN+>'0_"][J?BO0]'N$<.K:;]N
MA\,>&%MG`C2QECMEV(I$G]T-?E7!-&.?YQG?%^)]]SQ=3`97?_ESAJ+?-4C%
M_!4=XJ,E=KWM>WH8J7LJ5+#1O%J//55[W<K./W6EU>^R"BBBOU4\\****`"B
MBB@`IK*'!5@""""&`((/4$'J#QD=\4ZB@#^(_P#X*M_LPZG^Q+^U[H'Q>^$/
MVCPIX0^)&KK\4_AU?:1"+.#P?\0_#^JVNI>)M!TU8<1VT6G:Q]@\1Z5:C;:0
MZ9K::1#`UIIL\:_UL?LB?M`:3^U!^SM\+?C?I:06\OC/PU:S:]IMNY:+1_%N
MER2Z/XNT=-Y:58M/\1V&I0VC2_/<:>+2\`V7",WQ+_P6M^"5I\7/V&O&OB&&
MT6?Q#\%M8T7XGZ+,L8:X2RLYQH'BR`2A#(EH?"VN:GJ5PB.BM=:183,<V\>/
MB_\`X-X/B_/JOPR^//P0O[LR+X)\5^&_B%X>BD<DQV'C?3;S1==M(.HCM[*^
M\(Z?>2*#L,^N22`>9)(@_*,KI+AOCS$Y13M3RSB'#O&X>A'2G3Q4'[1."3?_
M`"\I5Z7V;I*7D=]1>WPD:TOXM&U+FWNDDKVZ7T^X_I"HHKF/%7C'PEX*LH-2
M\8^)_#WA33KBX%I!J'B36]-T&RENV1I$M8KK5+FV@DN9$CDD2!7,C)'(X&$-
M?JLI1A%RG)1BMY2=DM;:MZ'`=/17'>%OB#X&\<"]_P"$,\9^$O%ITXQ#4/\`
MA&?$>CZ_]A,XD,`O/[*O+L6IF$4AA\\QF4(Y484X[&E3JPJQ4Z4XU(/:4)*2
M??5=5V#5;H**Y+Q9XX\&>![>SNO&?BSPSX2M;Z:2"RN?$^OZ7H%O=SQ1B66"
MVGU6YMHYYDB_>M%$7=8U+L%0%AI^'_$>@^*]+@UOPUK6D>(=&NS*+35M"U*S
MU?3+GR9I()A;W^GS7%I,89XI(91%,_ERQO&V'4J!5(.3@I1<XI.4$TY*^UUO
M;SL!M44458!17+>*O&G@_P`$V/\`:?C+Q3X=\*Z<IYOO$>MZ;H=IGT^T:G<V
MT))P>/,SQQWKQ#_AL;]D[[7]C_X:2^!@N=VSRO\`A:O@G?YG_/,#^U\;L]LB
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M`R)/):1ZM>6CW"0O(B3-"KK$SHKE689Z+1]8TS7].M-8T74=/U?2=0@CNM/U
M32KVWU'3K^VE!,=Q9WMH\MM<P.N"DL,LB,<@'CG.-6$I2@IPE4A;GC&2;C?:
MZW5_-`:=%%%:`%%>3:M\>/@KX>U2^T/Q%\7/ACH&M:9/]FU#2-9\>^%M,U2Q
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MLY9K<3121&:)602(Z%@RFIE7I1@JDJE.-)KXY227E9O3\;AJ]$KL[NBO(O\`
MA?\`\"_^BS_";_PX_@__`.7%'_"__@7_`-%G^$W_`(<?P?\`_+BLOKN#?_,3
M0_\`!D/\_/\`/LQV?9_<>NT5Y%_PO_X%?]%G^$_X?$;P=_7617J=G>6VH6T%
M[93P75G=0PW-I=6TJ3V]S;SQK-!<031DQS031.DD4L;/'(C!D9E(-:TJ]&M?
MV56G4Y;<W))2M?:]GI<+-;IKY%JBL;7_`!#H?A72;S7O$FL:7H&B:=$)M0UC
M6]0M-*TNQB:2.%9;S4+Z6"TM8FFEBB$D\T:&22.,$NZ@X?@_XC_#_P"("W[>
M!O'/A#QFNE-;KJ;>%/$FC>(1IYNUE:U%\='O;P6IN5@G:W\_R_/6&0Q[A&^'
M*K3C4A2=2"J34G&FY)3DHVNXQW=KZZ=4+7>VAVM%%%:`%%8FO>)/#_A>QEU3
MQ'KFCZ!IL*LTNH:WJ=EI-C$%`),EW?SP0(`,DEG``')%>!S_`+8G[)]K=M97
M'[27P.BN4?RVB;XI^"PZ2#JCC^U\*PZX)R?;'//6Q>&P[2KXBA1<KV56M3IM
MV:O93DF[73=MM+[C49/:+?R\[=OZ_+Z7HKA_!_Q+^'OQ`@:Y\#^.O!_C&!55
MVF\+>)=&U^-5=2Z[VTJ\N@GRC/S8..O.:[BM*56G6@ITIPJ0>TJ<E.+^:T%J
MMT%%&:\*\:_M-?L\?#2\?3_B!\;_`(4>#K^/?YVG^(?'WA?2[^,I@L'L;G48
MKM6`/"-"';LO:HKXFCAX\]>K2I0M=SJU:=**U2WG*.]^E]M;#LWLG]Q[K17R
MII?[</['FM3K;:9^TU\#+J=F"+&OQ*\)QLSE@JHOG:I'N8L0!MSCN1QGZ,\.
M^*_#/BVQ34_"WB'0_$>G2*K1W^@ZOI^LV3ALD%+K3KBX@8'!Y#X/;-10QN$Q
M+:H8G#UG&UU2KTJK7->UU"3:O9VOO9V\G*$H_%%KU3\O\[&_111742%?.G[7
M.M77AS]E3]I?Q#9,4O-!_9^^,FLVCJQ1UN--^''B*\@*,I5E(FA7Y@<JVT@U
M]%U\\_M9Z#=^*?V6OVD/#%C&\E[XC^`GQ@T*TCC4M(]SJOP[\06-NB*.2QEG
M`51RSD+CFN+,?:/`XM4OXCPN)Y-]_85-K>=BZ7\2G_CA_P"E(_F`_P"#>70+
M6^_:C^,/B&50UUHGP,NM/M&."8QKWCGPBUQ)'D':^S2$BWCD)*Z\ARI_L%K^
M//\`X-ZO$EKI_P"U3\6?#<SJEQXA^!M_>V>XJ/-E\/\`C?P>98$R03(8-5DG
MV@_ZNWE<\(2/[#*^)\,'3?"F']G_`-!>-YO7V\[7\_TM<ZLP_P!XEOLM[[67
M?\?0****_0SB"BBB@`HHHH`****`/!/VHO#EOXO_`&;/C]X6NH_-@\0?!7XI
M:1(FSS&QJ'@?6;=7B4Y_?QR2+)`P!9)51DPP#+_+'_P;W:Y-:?M;?%+P\&S:
MZ[\`M;NY8R[*&N-$\>>`C;2A1PS1QZE=*&;E5E<#AVK^I/\`:N\3VW@O]F']
MH;Q9=R".'P_\$OBEJG+;#)-:>!]::WMU;(Q-<W`BMX.03/+$!R0*_ER_X-[/
M#\UY^U=\6/$VUA:>'_@-JFGRRB/<JW7B#QWX(:UBWXW(TD.CWCJ`PWK#(3G9
MD?F/%.O''`ZI6]M[;%>UV_A<M7V3^7[S^D=^%O\`4\7?;DBOGI_P#^Q&OY\?
M^#B$X_9I^".!U^.A'.?^A!\6_AZ]O_K_`-!U?SW_`/!Q'_R;3\$/^RZ'VX_X
M0'Q;WKWN/7;A+.GVPJ\O^7]$PPG^\T?^OB/Y^_@'XF_::_8HL/A)^VC\,&D3
MP'XYU7Q%X5NI@+JZ\*ZY-X;U:YMM;^'7Q!LHU1(6U6PM(M:T6X:16"R?:])N
MXM4TB\6V_M4_8R_;/^%'[:WPLM?B%\/+Q-/UFP6VLO'G@*_NHY/$/@?Q`\;/
M)87\86(W>F7/ER3:+K<,*6FK6BLP6WO(+VQM/S'_`.".WPI^'_[0?_!,[Q1\
M(_BGX?M/%/@K6_BO\1M%U33;I2DD?F6OA?4K/4;"Y7][IVK:9>SQW^EZC9F&
MYL+V"WNH&$J;V_(?XX_`K]IS_@CG^TGHOQ6^%FKZCK'PQU74I[7PCXRGMII?
M#GC+PW,\EU??#/XH6%JT5O#J\=K%ND53;K>O:P^)_#,UIJ=HT&C_`)_D=;,^
M#LNRO.*,:N-X9S+"8;$9EATW*MEV)J4XPGB*2L[J;BG**Y5-JS:Y=>ZLHXJ=
M2$K0Q4)\B<I6BZ:LE'LW'5:VL?I;_P`'&5N[_"_]F6Z$:E(?'_CV!Y"061KG
MPYHLD:A3@L'^QLS*O4QJ">:^X/\`@B8<_P#!.OX/'C_D8_BN!CIQ\3O%G?\`
M'GBOR-_X*L?M9?#7]MO]A_\`9U^,WP\F-GJ.@_&:?PYX_P#!EU<)-K'@3Q1J
M_@'6=0.E:DBK%]HT^\;1)Y]`UP116NJV,;R)';WL%_I]C^N7_!$S_E'7\'L=
M_$GQ9QQ_U4[Q9_D^]>OD^*HXWQ*S#%X:I&MA\3P]0KT*D7>,J526`Y9+JF[-
M--::Z[F56,H8)1DK2C7Y6O2.OYGZQU_/)_P5:_X*S^(_@!XEU']G#]G*:QM_
MBC8V<7_"Q/B'<P0:G%X&?5+)+NS\/^&K&=9+.Y\4_89[:\U#4]0@N;#1DNK:
MVAM;K53<IIO]#=?Y\_[:.C:QX`_X*$_'C_A9UM<RI!^T;KWBO4X[N.25M4\'
MZ[XP?Q9HUW#$Z@SV&I^$-4LWM((\0&WD6TCV*&">KXD9SC\JR?#4\#5>%>8X
MM8.OC(KW\/1=.4Y.E+_EW5GR\L*FO+9M)LRP5*%6J_:*\8P<N7O:VA^W_P"S
M#_P1T\3?M":)HWQU_;^^+GQ2\6^,/%]C9^(+3X>1^);MM0TO3-307MK;>+/$
M>L?VG?VU_+'*'NO#V@PZ;%H^Y+-K][B&6*W_`$$G_P""+7_!/*;2_P"S5^#6
MIV[[`G]J0?$7X@+JF1T<SR>(Y(&89/RO;-&2>4QQ7Z>Z#K>D^(M&TO7]!O[/
M5-"UK3K'5=&U33YX[BPU'3-1MTN;&]LYXB8I;6ZMY(YK>2-BLD4B./O5L9KV
ML#P=P_AJ$(3P&'QU5I3K8S'1^M8K$5&O>JU*M64VW+HEHO,REB*SDW&<J:;T
MA!N,8^22V/RZ_9G_`."2?[,O[+/Q;?XO^`-7^)^JZO:P/%X>T7Q+XM2;0=`F
MF5HI[M;;1]/T:;6YC`[P6\7B";4[*U5S-':F[2WN(/U%HS17N8#+L%EE%X?`
M8:EA:#DY^RHQY(*3W:2[F4YRG)RD^:3M=]7;T/PG_P""O?\`P4Q\2?LI6^B?
M`WX(S6=M\9O&7A__`(2'6O%MQ#%?K\._"5[=SZ?93:=8W$<MG<^*=;FL]0>Q
M.HQR6^CZ?:?VA)9W,]]IY3Y-_8B_X)13?M?^`_#_`.U'^VU\4_B?XUO?B1`?
M$OA7P@OB:[&HW/AB^D=]-UGQ-XEU-=0U"./6XE-_I>CZ`--2RTB>QD>_,L[6
MEK\&?\%RO#'B+1/V^?%NM:Q!.ND>,O`'PXUKPG<.K^1-I-AX>A\,7T5NY&S]
MQXAT35R\2L2AN$9@/.0M_5[^P/XPT/QQ^Q=^S)KWAV:";35^"?PZT%Q;NC);
MZMX4\.6/A;Q!8N(P%6>QUS1]1L[E,!EGAE!`Q7Y;E\'Q/QOGN$SN<J^"RA2A
M@<M<JD<)-1J4X>WK4HS@JM5*2;E).^R25ST:D5A\'0J4G:I62E*HOB5U=)/I
M;7U\GO\`.$G_``1@_P"">$E@+#_A25\A"&/[<GQ%^(8O^A7>)CXH,8<9SE8`
M#W7IC\I/VYO^"7?B3]A_P;J?[4_[$OQ6^*'AK3_`CV^I>-?"W_"27,>OZ)HL
MES%`->T37])73Y=6TC2[B>$:QH^N6]T\.E//J,M]>6]I=6LG]5.1TR,U\G?M
MV:GHND_L8_M27GB"6UBTL_`/XJ6<ANF41R7>H^"]6T_3+90S*LEQ=:K=65M:
MQY!>YFB4?,1GZ[.^%,BJ9;C*E'`8?`8BAA<16P^+P,%A*^'JTZ?/&<:E!TF]
M8)>\WULUUYZ&)K*K!2G*<92C%QFW*+NTM4^W0_-G_@D7_P`%-_$O[5[:O\"O
MC>;&7XQ^%/#A\0Z'XOM(8K"+XB>&M.N+6PU'^T+"!([.T\5Z3+=VMS=_V;'%
M9ZKIT[ZA%9VLEC?;_P!V*_AQ_P""'^DZQJ7_``4'^'=YIB3-9:%X*^)VJ>(7
MC4E(](F\'W^BPFX(&%A?7M6T6$$G!G>%0"S+C^XZN/PXS?&YQP[&MCZGMJV&
MQ53"*NU[]:G3ITIQJ5']JHW4<9S^TXW*Q]&%&ORT]$X1E;M>^GW+R]#^2?\`
MX.*?^2W?L[_]DK\2?^I:?\]_Z5^]?_!,C_DP?]EK_LE6D?\`I7?U^"?_``<4
MY_X7=^SQ_P!DL\2?^I:?RK]Z_P#@F0<?L#_LM<@?\6JTCK_U]7]>1D#_`.-C
M<6_]@D?_`'2+K/\`V&A_U\?_`*2OZ_X-C[NHHH!STY^E?JIYY^,__!3W_@EQ
MX9_:[T.Z^*GPJM-/\-?M&Z%I["*XQ%9:1\4=/LHQY'A[Q/)M\JVUNWA40>'?
M$K_/`_D:?K#S:0L4VF?DA_P36_X*6>-?V//&;?LH_M71:[I_PSTW7KGPW97O
MB2"[3Q%\#_$*W<EM/87\$X>YD\#_`&MR+VSC$DF@.\^K:6'TMY[63^P>OQ*_
MX*\?\$\OA_\`'SX3>./VC/#,=EX2^-'PD\$:[XNU+6H+=8K'X@^$?!VDW&L:
MAX?\211+NFU>UTVPG'AO6CNN(&C31KWSM,FA^P_G7$W#V*P6)_UHX:?L,UPU
MZN.PW-:AF6'BDZD94TN66):NE)_'?75*_=AZRE'V%76.GLWU@V]?6^F[5K?=
M]Y?M7?ML?!G]DGX/)\7/&^MV>KV^NV@_X5WX<T&_M;O5?B-JMQ;+<Z?:^'7C
M:2!],DBFM[J_U]BVF:=I\\5R\TLMQ96MW_++\*?A3^T[_P`%H?VFM5^)/Q)U
M6^\,?"/PU?Q6?B#7[2*4^%OAYX8$PNK3X>_#FSNE:WU'Q3?6I26>:4,Z_:!X
MB\1-(&L;"^^6OV+?@CXZ_;^^/WPI^`7C3XF^(8/!?@7PIJLT=SJ%]<:K<^%/
MAOX>O&U;4?#O@RTNWDM;*ZU&_P!3BM+(.AM;(W1OI(9K73+>Q7^[/X._!SX=
M?`3X>^'OA;\*O#5CX5\%>&+-;33-+LD^=W.7NM1U&Z;,^I:MJ5PTEYJ>J7CR
MWE_>32W%S*[L37BY?+'>(]6&+QJ>!X:P-:,?[/A6A4JX_'4X4YRAB90:3HP<
M[.$DE*]T^AI44<#>G%<U=QE&4WHHI\MK+WNSO[RU[E/X'_!#X;_L[?#?P[\*
M/A1X=M/#7@WPU9I;VEI`BM=7UV0/MFLZQ>X$VJ:UJD@%QJ6I71>>YGR25C$<
M:?,G[4__``3?_9E_;%\9Z#\0/C7I'BN^\3>&_#,?A+3KKP[XLO\`P_;_`-B0
MZIJ.L0PW%K`DT$TT=_JVH2I<!$E*7'E2&1(H5C^]J*_4*^68#%82.`Q&$H5<
M''V?)AITTZ,?9?!:']V_?4\^$Y0DIP;C);-'\[O[8'_!'/\`8N^#7[+WQV^*
MG@;1?B%9^,/`'PT\2^*_#L]_X\O=2LHM5T:Q>[M&N;*XM/*N86>,1S1,5+PL
MZ*Z%MU?DU_P2%_8P^"O[9WQ.^+?AGXV6GB.]T?P7X%TC7=&A\.Z[-H,HU+4=
M?33Y);FXMX999HTME94A#1KF1F))"[?ZMO\`@HG_`,F*_M5_]D0\=_\`IEG^
MO3_.*_GZ_P"#=7/_``NW]H<#`_XM?X8_'_BK#[C./_KU^39[D>44>.N&,#2R
M_"TL)B:-=U\/3I*%*KIB6W*":3U^Y]SU*%:L\%B).I)RC.*@V[\NBO9:*[NO
M2WF?J(O_``0J_8"4_P#(N?$[&1N4_$G5`&`(.UL6P8`XYVE6]"*_7?PYX?TO
MPIH6C>&M"MDL=$\/Z5I^B:/8Q;C'9:7I=I#8V%I&SN[LEO:P10H78MM09)/-
M;=%?JN!R;*LLE4GE^`PV#E5BHU'0IJ#G%;*5M[:V[-MGFSJU*EO:3E.VUW>U
M[?Y(_,W_`(+#?\HX/VD.W^@_#/\`'_B\GP[X_P#K?_KK\F/^#<9BVO?M:\#(
MTOX*GZ_Z5\3AZ<=?2OUG_P""PW_*.#]I#/\`SX_#/MT_XO+\.O\`/;^A_);_
M`(-Q,_V]^UM_V"_@K_Z5_$WM_P#7_E7Y[G'_`"=#AW_L5S>_][&;?=M^IVT/
M]QQ'_7V'_MA_4W7XD_\`!5G_`(*AS_L>IIWP<^#UMI6K_'7Q-H@UR[U75(UU
M#1_AMX=O3-#I^IW6G`[-2\2:K-:W,FCZ7=$6=I:VXU;4X;N&?3[#4/VVK^$3
M_@LGX:\5^'_^"@_QKO\`Q/#=K:^+(/`WB/PG>W"R""_\,'P/X?T.V:P:0`-:
MV&IZ+JFCE8U5$NM/N$PS[G?V/$7.<?DN0JKE_-"MBL53PDL1'1X>G.G4G.I&
M6\*C5/EA-)\MVTF[(SP-&%:ORU-8J$I6=]6K::-=S]&_V2/^"9OQ<_;V\,Z+
M^TY^W1\<?BEJN@>-8_[;\$>"8=9;^WM4\/7,C266MW=SJ<-YI'@_0]5C!N=%
MT30-$2:;2I;2_%QI\-Q#`WZE6W_!%G_@GE;Z9_9S_!O5+N39L.J7?Q%^(+ZI
MR!ND6>/Q)#`DC,-WR6RHI)"QA>*^T?V5/$_ACQC^S5\!_$/@RZLKKPU?_"+X
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M_@N[^U5^T5\,O$/P\^"7P]U+Q-X`^%?C#P5/XC\1>,_#TEUI=UXXUV34M8TV
M^\%CQ%9-'/9Z?H6FV-EJ.IZ597%I-J1UV#^T/-T];=)>7_X)D?\`!/C_`()[
M_'SX,>&?B#\1_&<7QH^+^MQ75YXR\"7OCVY\-MX(OWO[F)-&E\+Z/J&E>(;M
MFMD@F;6]2O+JQU8S_;-+$5LX#?T?_%KX-_#'XZ^#[WP%\6O!?A_QWX1U`$SZ
M/X@L(KV&.<*5BO;&8[;K3=1MLE[74M.GM;^U<;K>YC8DU^'GQ8_X-^O@OK.O
M7'B'X%_&?QW\('DD:>#0M2L(/&^G:=(SE]FE:D-3\/\`B&WMTR-D=]J>J7(P
M#]KQD5^=9QPUF\.(*N>1PF&XFPE6+A2RS'5U1>`C-1O]6A55:A6Y;)RYZ5Y+
MELJ;OS=5*M3]BJ3E.AROXH7ESWM\2TVMW>[VZ_7?BG_@B[_P3U\36#6EK\']
M3\*3E75-2\+^/_'%M?1,P(#JNJZ[J]C(5RQ5+JRN(B<%XWVC&+^S%_P2`^"7
M[+/QLMOC#X)^*'QAU:WTNWF.B^"-6\106&C1ZG-F)+[7+GPU!HDGB>UM;=C'
M:Z3JMNU@9=D]]'?F&!(_SDU7_@F-_P`%4O@'9/JW[/7[8>I>-K?3%-Q:>&8?
MB!XR\*W=W'#E_L\&@>++C5O!]S)(%!^QWVKP6DN2LA;Y$D\R_9S_`."U_P"T
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M!_=."",@@@\@CD<\C\QS7\GG_!?;]E"]\.^//!W[6_A;3G;1?&]O8>`OB=+:
MQMBP\7:';N/"7B*\:(%PFO\`AVW30O.9T%O=>%],B+F748Z_7C_@E!^VA8_M
M9_LUZ-9>(-5BF^,7PCL]+\%?$BSGF5K[5(;2U-OX8\<>6S>:]OXITVS+7LY1
M5'B&RUM?+BA,`;\JX-K1X>SS.^$<1[D98J>892^E:A6^*C"3MSU+*#A&]W:2
MT:U]#$Q]M2I8F+YGRJ%9V^&UE!OKK>6MO2Y^IE%&:*_53SPHHHH`****`"BB
MH9YXK:)YIY$BAB1Y9997$<<44:&22621B%1(T4L[,0``22`#1>WY@?CQ_P`%
MP?CE9_"O]B7Q!X)MKQ(/$_QR\1:)X`TFW279<_V)9WD'B?QA>^6I#/9#1]'7
M0;OHC3>(K.W<@3\_+_\`P;S_``=N-"^#OQL^-^I6C12?$7QGHG@GP_+-%M>7
M1?A_I]Y?:C>VY))>"^UKQ;+I\Q)*F;P^8L?N2S?D_P#\%)_VD/$'_!0G]L[0
M?AS\&XYO$O@_POK-M\'_`(/6%DS2VOBG7=7U:WM?$'C&!AN2.U\0:N8(K>^;
MRUC\*>']-U&Y\L-=1)_87^R_\"M"_9I^`OPQ^!_AUEGLO`7ABQTN\U!(_*&L
M:_<M+J?BC7#'U1];\1WVJ:JT;$M#]J$(.R-57\HRBHN)>.<7GD'SY7D%%X'"
M5EK&IBIM4ER:+[53$57NUS1CMJ=]5JAA(T6VZM6U1QT22=G:]W?9=%?LEJ_H
M*OQ5_P""W'[//QH_:*^`?PG\._!/X?:U\1-<T#XNIKNLZ7H9LOM=AH[^#O$N
MG?;WBO+JV\R!;R[MK<^2797GCW*`<U^U5%?H><Y71SK+<5EF(J3I4L72]E.5
M-0YTE.$[QYXR7V+=-'Z')2J.E.,TKN/38_(__@C#\$/C!\`/V4/$/@7XT^!-
M:^'OB>?XR>+/$%AHNNM8F\FT/4/#7@JSMK]5L;N\5(9KW3=0A02O'(QMV?RP
MK+7Z3?%WX1?#[XZ_#_Q%\+_BCX<L?%7@KQ38O8ZMI-\G?*R6U]97"XGL-4TZ
MX2.]TS4K1XKS3[V&&ZM9HYHD<>E9HHP&4X7`97ALH2]OA</AHX7EK+G]I22M
M::>]_5V%4FZE24[)<TG*W17/XE/VI/\`@CG^UI\(/B-K_A7X&>$?%/QL^#VN
MW4.MZ!J^@7&G1WD,-H;]-,TOQKI$U]8I_P`)'H*7MQ;VNIP6TEAJ%I<SWM@U
MG<7E_96?])?_``2B^$OQ(^"'[$'PO^''Q6\)ZCX)\;:1J_Q%O-3\-ZLUJVH6
M,.L^/_$FJZ>UQ]CGN8%^TV%W;74:"7>L<R"5(WXK](**\#).",KR#-<1F>7U
M<5#V]*=%86I4=2A0ISJ4JCIT92O55-.E:,)SFH\SY6M4]JF)G5IQIRC%*+O>
M*MTM:R"OR]_X*`_\$Q?A7^W!IMCXB;4W^'OQIT#2SIF@_$/3[%+RVU33H6EF
MM=!\8Z2LD!U72K>:>5K*[MKBVU;3#+)]FNI+=Y+.7]0J*^ES'+<'FV%G@L?0
MAB,-4^.G.*=G]F<&_@J0UY)K6-WW,(3E3DIP?+);,_E^^$?P_P#^"S'_``3W
MM!X$\&>!?#W[2_P:TN9_[&T&TUB+Q-8:7:/([!?#<4^I>&O'OAZ*0+YK:0MI
M?:+9SR/)!:2,QD;ZFL/^"D__``4+O4.EQ_\`!+7XD'7U0(TLFM^)+#1C*2,,
M)KSP5$BQ;26(.HY4?(6;;NK]VZ*^<PW"N)R^G[#+>)LZPN%3_=X>K'+L=&A'
MI3HU,;@JU6%.*T4>=V[Z*V[KQE9SI0E/K*-X<VVZ5T]E\[L_(CX`?%;_`(*P
M_$#XMZ!J_P`8/V=?@K\*_@?.?LOB+P]?^+#'XR@L)Y8V76M)O=-U;Q=>7>L:
M=&69=*U#2M*TV_#S6D[:=,8;VW_7>BBOH<NP-7`494JN88[,92FY^UQTZ,YP
MYMX4_8T:/+372#YN7H]7?&<E*UH1A;^56OMOZ6/AC]N3]A#X4?MP?#RS\+>-
MVNO#OC'PR;V[^'_Q%T>VAEUGPQ>WD`BN[6X@D,46K^']26.%-4T:>:`2B*.X
MM+JRO88;I/Q@^"?P9_X*S_\`!,Z76_!GPP^'7A?]I_X'7^KS:O'H.D:F+Z"U
MNIMB3:EHVF37^B^,/#&IZA''$VH65M9:]H32H)O*N;A7GD_J&HKR,SX5P&88
MV.:4:^*RS-H+E_M#`3A3JU(:7IXB%2%2E7I.R]RI%I=&KLTA7G&*IR4)TD[J
M$HZ+T:>A^&"_\%.?VY8X?LUQ_P`$K_C*VK@^47AU;Q1_9WV@Y^;S#\.)/W(;
M;EA<,I!)#\8/RA\>?!/_``5V_P""D=E:_#;Q/\%O#_[,GP0GU.UOM6TS7M:C
MTM-3^PW,=S9/XIN)KS4_&?B*/3I<7MEIVF>'-,TF74H;2YN+3S+6.X@_I^S1
M7/B.%\3CJ,L+F7$6;8O!U&O;8:G#`X*->*T]G6J8;#0JSIR^U!3BG^`XUU"2
MG"E!36SE>=MMD]%M_77\XO\`@G]_P3F^&G["OA+5#IFI2>-OBOXPMK2+QS\1
M+RT6R\^VM9!<P^'O#>G[YFTCPW!>`W,D,EQ<7NK72Q7FIW#M;6%M8?H[117T
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M,:4H0FH_#)K57M?3;H?@A_PW)_P6`_Z1O:-_X,]:_P#FKK];OV9/&?QD^('P
M5\(^+_C]\.].^$_Q3UJ/5Y_$'@#2[R6_A\/P0Z[J=GHD<T\US>.+R^T2WT[4
MKNW-S,;.>\DM)&2:&2*/Z!HKV,MRG&8&M.KB,\S',HRIN$:.+CA53BW;WTZ5
M"%2Z2LDJD4^J>ELYU%)65.$._+?7;>]^S^_[RO!?VH/#6N^-/V;?C]X-\+:;
M-J_B;Q;\%OBEX9\/:3`T:3ZGKNN>!];TW2=/A>=HX$FO=0N;>UC,TL46^5=T
MB`YKWG(]12UZU>C#$4:M"I\%6G4I3MI+EJPE!V?1^]==[6,T[24NS_5/]#^4
M;_@CQ^Q+^U7\!/VOO^%@?&+X)>+?`'@^'X6^-M);7M>.E1VC:GJ-SH'V*QC%
MKJ-U,\]PL$[J!"56.&1W9<#/]7-%%>1P[P_A>&\O>78.I6JT77JU^:MR.?-5
MY;KW(Q_E6KO?R-:]>>(GSRT]V,;+RZW\_P``HHHKW3$^5/VW_!GBKXC?LB?M
M$>`O!&BW7B/Q?XN^$GC+0_#FAV+0K>:KJU[I,T=G86QN)(8/.N96$4?FS1H9
M&1"V7%?B]_P1#_9)_:2_9P^*?QQ\0?&[X1^)_ASI/B#X?^'=)T2\U_\`LY4U
M/4;?Q%)>SVUHMG?7<SRPVZ;W)C6-0Z[I%9D1_P"DRBOGL;PYA,=GF6Y]4K8B
MGB<LISI4J<'#V4XS]I?G4XR::=2_N[VUWTVC7G&C.C'13ES-]=DK6^04445]
M"8GP/_P4Z^&7C[XQ_L-?'/X;?##PS?>,/''B6Q\##0_#FF&W6_U(Z1\3O!.N
MWZ6QNIH(=T&EZ;?7;*\JED@8)ND*1O\`F[_P0U_96_:$_9MU/]I&]^.'PN\1
M?#B#Q?9_"JU\.-X@_L]'UB;19?'LNJBTBLKV\<K9#5M/\Z23RE!G"KN*OM_H
M:HKYS$\-X3%9_@.(9U\1#%8##2PU*E!P]C*$O;7<E.,K->V=K)/17;N;*M*-
M&=%:*<N9RZZ6MIY6"O@G]NG]@'X1_MR>"+#1O&KS^&?'?AB.Y;P'\2='MX)M
M8T"2Y3-SIE_:2M%%KOAN_D"2WNC7,\&V1?M=A>6%V7G?[VHSGI7L8[`X7,L+
M5P>-HPKX:O%PJ4YI--/K%OX9QWA-:Q>QG"<J<E.#Y9+9G\M'PO\`V9O^"O?_
M``3BOM1TCX#6WAG]H;X.-J$^HGP=::E:ZGHDYDEEDEO;3PKKNJ>'/%GA?6+L
M'=>P^$[Z[M+N=UENFU.6,O7UGI?_``4H_P""A\2QZ3K'_!+;XC77B';L:?3-
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MNI65PTN^RL--\*ZQ+!!9I')+<W-U,^SYZT?_`(*/_P#!4+PAY=C\3O\`@FQX
MC\23Q*HEO_!.F^.M*BF9<*[A8K/QU9-O`#((KN*,`G`;;D_T)45Y-?A[&RQ-
M?$X7B7.<+*O/VCI-X;$8>F_Y:5*K1_=TTM(P3TO>[TM<*RC%*5*E*VSY>5].
MWH?SZ^(_^"@__!4CXDZ=+HGP;_X)S^)O`>MW8-O!XD\=PZ]J5MIS3?(ES%;Z
M_8>`]'CDAD"NLNIW-S8J0!<02(<-\]_LP?\`!%[XV_$3XT+^T+^W;XFTU)-3
M\7/\0/$/@#2]2M]>\2>-/$,^H'6'@\6ZSI:)X>T72)K\[;_3M$FU.6ZL5;38
M'T=)0\']1V:3</4?G7+/@ZCCL3A\1GF:8_._JM55J&%Q'L*&#A65FI_5L/2B
MI/2-E.4K6TM=WM8J4(2A2A&CS?%*'QZ;6F]59_?U$50@PH`'```P`````.P`
M``':G445]D<H4444`>5?&WX-^!_V@/A=XS^$'Q'TX:KX,\<Z'=:+JULH1;FW
M>4QS6&KZ;.Z2?9-7T34(+;5=(NPC?9=2M+:XV2&(+7\2FIV'[1O_``1]_;+2
MXME>\M]/FG;3KJYBN+/PA\:?A->WRO+;3$-,J2F&UC-W`KS7_A/Q;81W$*3P
MV5K>7W]X%?*7[6_['_PB_;(^%]U\-OBIICF6#[1>^#_&6F)%'XH\#:^\6R+5
M]"O&C<^6Y$<>IZ7<>;8:M:@0WD+216]Q;_$\7<+SSFGAL?EU;ZGG>63]K@<3
M'W?:-<O[BK)._++E]V5GRW?NV9U86O&C.4:BO2JQY)I>NC\[79:_9._:X^$/
M[87PNL/B9\*=9BE'EVUOXI\)7L\*^*/!&O21;Y]$\0V*L7A=2LC6%_&K6&K6
MBB[L9G0R)%]1U_"=\5_@%^VW_P`$E/C+#X^\*ZSK6F^'S>&S\._%OPI:7-Y\
M/O'.DM,)HO#_`(TTBX^TZ?:75U'!`+[PGXE1BUW&UQH-_?FVM=37]K?V3O\`
M@O/\$?B'9:9X8_:;T.X^#7C1EBMY_&6CVNH:_P##36+DA(Q>&.TCO/$OA8W4
MS`"UN[/6-/M@=\^N10CY/-R3C[#N7]E<34Y9-G.'E[*H\4G2PF(<4KU57<52
MI7T?+*5GS>[)V=M*V":3J8=QJTGK%0=W%:?%UUNNG?Y_T"45YO\`#CXO_"WX
MNZ2NN?##XB^"?B#I+I'*+_P=XFT?Q##&DJAD%R-,NKA[27!&Z&Y6*9#P\:GB
MO1\CU%?HE*K3K0C4I5(5825U.G)3B_1IM'#KV%HJ.6:*"-Y9I(X8HT:2225U
MCCC102SN[D*B*`2S,0``23BO@O\`:!_X*7_L;_LWV-]_PFGQC\-^(/$EH)5B
M\#?#N\M_'/BR>YCW?Z)-:Z)--I^B3$H_S>)-1T:`;''F^8!&V&+Q^#P%-UL;
MBL/A:*OS5*]:%)*W92:<O.UVBX4YU)*,(N3?9>G^?ZGWN2`"20`.23P`/4D\
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MW.K_`.")_P#P3IOOAU86_P"UW\:=$DL/&OB/29(/@UX7U.TV7WA?POK-J4O?
M'&H03`O::YXGTZ8V>AP%4EL/#=U=7,YE.O+#9?T=U%%$L*A$`"J`J@``*H)V
MJ`.`%!PH`Z`9R<FI:_0,AR3"</9;1RW!K]W3O.I4<;3KUYV]K6GJ_>FTM+NR
M5KO<XJM65:;G+KI%?RQ6T?E\O0*_._\`;^_;AU;]B[3?@O)H?P\T?Q_J7QB\
M>S>!H%\0>+Y/!FCZ`Z6]C(FJ:EJL6B:V%LEEOXOMD\D,:6=I'-<YE9!"_P"B
M%?EK_P`%-_V,?B=^V%I7P"B^&LWPYDE^$WQ*NO&>OZ'\2[[6+'0?$NE/;:<H
MT60Z3H>O--!?267V;4(;FU6)K">;8SR;8GCB*>90RG$SRE2ECX^Q]A&"@Y2O
MB*/M+<\9+6ESQVT4F]TAT?9^TC[6_L_M6W,#XU_M_?&?]G?P3>^/?B)\.?V5
M/$&F:7LEN?#?P]_:]^U>.=3A:XAA,?AGPWXF^$FAMXBU%5EWKIFGW,MW.(Y#
M%&0@W?H5\!_BROQR^$G@7XK)X.\5^`%\<:!:Z]'X1\;V*:=XET>.Z>=(XM0M
M8Y95$=RD`OM/N-T9O-+NK&]:WMS<>0GYA?$W]C3XR_$;P7K_`(3TW]C_`/X)
MS^`M5UG2KS3]-\;6LWBG4]7\+W-RJQIK>B0Z1\&_"U^NL::1]KTN>#7+#[+J
M$5K=%I8X7MY_M[]B+]GKQ[^S%\"='^%/Q&^,.O\`QL\1V&IZCJC>)M<2[6'2
M+345M?)\)^'SJ5WJ&J-X>T=[>:2Q;4;V><R7MR8H[*S^RV%KYF55,[_M.4,1
M#$U,MJ8-252<*-.-+$1:L^=PH5ZKK)O2E1J*GR+GY5)<UU(T^7FA)W3U3](K
MNW?OJ?7U<EX[\3_\(9X+\6^+19_V@?#'AC7O$0L?-\D7IT32;O5/LAF$<IA^
MT"U\H2B*7R]^_P`M@,5UM<5\1O#UWXM\`^-O"MA)!#>^)_"/B3P]:3W)D%M;
MW.L:->Z?;S7!B5Y/(CFN4:?RTDD$08QQN1BOJJZJNE55'2K[*HJ7;VG+[F^G
MQ'.O/8^9?V#?VK[K]LW]GO1_C?>^"X/`5QJ?B+Q/H$GAZWUJ37XHCX=U$V(N
M5U&73M+=ENEQ)Y1M?W1)`=QS7V?7P+_P3;_9@\=_LA_LPZ%\%_B-JOAO6/$^
MG>*?%^OW-[X4N-2N]&^S^(-5:ZM((;C5=,TB\DFA@5/M&^QB1969$R%W'[ZK
M@R5XUY5@'F,91QSPE%XN,DE)5VGSMI72;=M%_P`!:57!U)>R34+^[>^UO,*_
M-"?]O_6OB?\`'WXA_LY_LH_"&W^+GB?X02M9_%?X@^,O'"_#SX8>#=7BU*?2
M+C18KVR\/^+O$GB/4;?5+34-/FCT[084^UZ7J8MWN;:RFN5_2^OR3T3]AGXO
M_LU?M,?%S]HK]DCQ/X`UG0_CS=W&K?$_X*_%]]>T738]?GU:^\1'6/!_CSPQ
MIGB"^TV0:QJNKSV^G:GX:O[2QBU2YM`UU$NGBPY\ZEFD99?]057ZM]:?]IRP
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M/]JX?M9+^QM_PS?\$S\4F\$GQ_\`VN/CSXM_X0A=!^PF[!;4_P#A3G]N?;MP
M$'V5?#Q3S<-]H$&Z6/\`2;X2ZQ\:M7TG5)/C;X-^'G@K7(=16/2+/X=>.=>\
M=Z;>:5]FC+7=_?>(/`_@:>SO#>"XB2R@LKR/[.D<SW2NYA7XL;]D#XBG_@II
M'^V:-9\*?\*U7X*M\/3HINM47Q=_;K6;V9E^Q?V4=+.FJA%R;C^U_.Q^Z^R[
MUW5^E]?/Y)0S+GQ\LPQ.*:I9CB*6#IU%AXPJY?#D^K56J=&+GS>_:HVI22VC
M;72HX>[R-OW4YWZ3?Q+6^VFO7L%>8?&GXA_\*A^#_P`4OBJ=+.M_\*T^''CC
MQ^=%%U]B.K_\(;X7U/Q$=,6\$%T;1K]=--HMR+:X\AI1*8)0A4^GUX[^T!X#
MU7XI_`GXS_##0KBRL]:^(WPG^(W@/2+S4WGCTZSU3Q?X,UC0-/NM0>VAN+A+
M*WO=1AEO&@@FG6V60PPRR!(V]S%^U6%Q#HK]\J%=T?\`KZJ4W#\2(ZRBNC:N
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M0TGPD^A?$KP!\)OARNA26>F>$/#?P<\0ZSKGA:U\-VUC`D,/DZQX-\&)H\MG
M<"6VM]/T^QN+,6<<$BR02,]NGS?#U;-90PL<V6.CBOJK==5J,_8^V3CS-SIT
MEAH/:UJTN;HE9WUK*FI_NG=?ITU]-?\`,]SI"0H+,0``22>``.I)I:BG@CN8
MI(9E#Q2QO%+&P!62.0;9$8$$%73*-QG:QP0>:^L,3\R?!W_!0?7/VD/B%X[\
M`?L8_!NV^+VD?#.]@TOQK\8_'GCF/X;_``KLM3NYK^*UL_#\ECX=\8^*O%AN
MAIE[+!<:?H-K;M;PI>>:;&[L;NY^E/!/BG]KQ_&&E:=\1_A-\"K3P3>B8ZIX
MH\$_&+QG?ZUHX2%WA6+PQKOPETR/5Y)I0D2HNMZ>BQL\TTD1C2.;XJ^!_P"P
M_P#M`?L.>+?B,W[)'BCX6>.O@S\2O$/_``E-W\(?C8WB?PUK?A/5DMVM%7PQ
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M,_9,_;6^'?[2'P`\`?&3Q!K/@/X;ZSXPM=:?4O!-YX^T2ZNM!NM'\2ZSX?:W
MFGO6TFZ;[7'I46IP^?IUK)]FOX/W;KMEE]<_:A^&>N?&C]G7XW_"/PU=Z?8^
M(/B5\+/''@?1KW5WN(M+M=5\1^'K_2K&:_DM+>ZN8[-+FZC:YDAMIY(X5=EB
M=L*?EG]C/]@/X:?!3]F[X:?#+XR?"CX(>.OB3X9L=<3Q5XJC\"Z#XB_M>]U7
MQ9K^N6T@UGQ#X<MM7O\`[)I>I6&G&:\AC<-9M#&@@BCS\WB*F<K.Z,,)&G+*
MWEE1U)5W.%'Z[];A"%JD*=1JKR2ERP<5S*/Q::;14/92<OC<ERVW26^G7FNO
M2W2Y>\$_M[Z5X]_;R\5?L<>'/#.@ZQH/AOX6P_$!/BEHOC&VU>&]U`VGAR]G
MT--)L;&6S06\7B".*2;^VFN$GMV+6@1OE_1.ORI^&?[!.K_"O_@HYXS_`&J_
M!]A\-?"7P6U[X/1^"-,\$^$[&31-7M/$4EKX5M+R]?0=.T2ST"&UN'T&YNIK
MN'4&N9WEB$MOYA+']5JZLDGFDJ6-_M6*C6CF.*C0Y7>#P:Y/J[IRLG*G;FY9
M2C%O6\5853V?[OV:_P"74.;SG9MOROIH%%%%>T9!1110!X/^TQ\89OV??@'\
M5OC3!H">)YOAKX,UCQ7'H$M^=+CU5]-MQ*MF^H"UO6M%E;`:86LQ49VH6P#D
M_LF_'6;]IC]G;X6_'2?PW'X1G^(V@3ZS+X;BU)M832G@U?4](:!-2:ST][I7
M;3S,KM9P$"3RRN4)*?M<?";7_CM^S/\`&KX.^%;S3-/\1?$7X?:[X7T6\UJ2
MZATFWU+4;4I;2:A-9VE]=Q6OF!5DDM[.Y=`VY87P16'^Q/\`!7Q-^SI^RQ\'
M?@EXQOM'U/Q/\/?#=QI&LW^@37=SH\]U<:YJVJYL)KZSL+N2*.*_CB+SV=NS
M.C$1JI6O%4LP_P!8%%0G_97]E2ES\J]G]>CC865[WYO9MNUK6UZ::J,?8\U_
M>Y^1*VMN5._WZ>OR/JNBBBO:,C\/?#/_``67T>W^,WQ2\(_%GX'ZUX&^"WPV
M^,>O_!?4_CMHNN7'BS1_#GB>QUW6M)\.3>.]%M]"M;O0=+\31:%?21:C;W%X
MEE=0RVHAO%M[B:+ZV_;#_;OT[]F71_V<?$/A7PII/Q6\/_M`?$W0_!%CK.G>
M+(K/3;/1-:CLYH/$.D7]CINM6NM?:+:\2>R19;:TEC1F>\4$8\S_`&/?V"_$
M7PC\6?MT?\+PC^'?C[X=?M3_`!4G\8:/X9MUO=;@?PY=Z[\0-3N+#Q7INLZ+
M8VD-VUMXKTM$BL9]3BCN;*6>*[C:.W9OD?XN_P#!(;XOP>,/AMX9^`'QATI?
MV8?"/QG\,?&.R^$OQ3OM>O=5^&.K:7?2-K>G_#?7;;2]9FO]`U?3[FXDAT35
M9M.6#44CNKB[O+M3J4GYU[;C.CE523I5,7BL5BW3I)K#4,3@(QS&-*$I17+&
MOAL1@U[3VSE&I251_NY))OM7U5U%[K4(J\EJ^>Z[KX;/UO?I8_H0HHHK]%5[
M*^_4XC\_OVA/V^?"7PA^,W@S]F/X=>`_$/QQ_:3\>0QW6D?#;PYJFE^'-+T3
M3I;"_P!635?&OC'5_-L=`L_['TS4=9*6]CJMZFEVANI[:!;FS-SU1\9?M[QV
M\.H?\*)_9JN"YB:;P_'\?_'D6IV\4A`>/^UY/@D^FSW$'60K`L4F&\IFXKQ3
M]H+]@SQCK'[4?AK]MG]FSXC:#X%^/6CZ*GASQ'X<^(.@7GB'X;>/]$31)?#A
M@U)M*NK37?#M^^A/!ITVI::]Z98=+TIX+:UO+>YNKWV^V\2?M[2VHL;CX0?L
MN66HA"C>(/\`A=WQ)O-)\Y0H^TKX;3X,6VH&%\NRVS>(%=541M>G<'KY*%3-
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M)[6^TZ_@N;.Z@D7`:.>%U.!QZ_AU^TO_`,$&?V<?B?=:AXC^!?B37?@+XBOF
MEN'T.W@;Q=\.7NB6D/V;0;Z\L];T$3RN?ETCQ`-+M(QBVT3"^3)^\M%>-FN0
M93G5+V.9X*CB8QCR0FXJ-:$=-(5E>4=M;67D:4ZU2C+FIR<>ZZ/U1_%-XS_X
M(E?\%!OA+JSZC\,HO"GQ`^RR/-8ZQ\-_B)%X7U=`&58Y&M?%\G@NXMKMD"N5
MMM0OUC`VI+*\88<S'^S]_P`%K?#RC3+2S_;%MXH,*L6E_%+Q/=V2*`%40SZ=
MXUN+)QP3^YD)!/SD_+C^W^BOCI^&.4Q:6$S7/,#3_P"?5#&IPZ6TJ4YVMY6N
MG9WL=*QM3K"G+U@OT/X>)_V`?^"NWQO\NR\:^$_C1K5A*P\Z;XL_&*PBL8U8
M@AIM/\3>.)KYL?-S%IUU*NQ=T;!]I^N/@C_P;U_%;5KNTU+]H+XQ^%O!FEF1
M9KOP_P##6UO?&'B.X0LKFV?6]8M-#T32K@_O,W-O8^)X]SDB*7/F+_6?15X7
MPPX?IU%5QM;,<TDMX8W$1=&=K?%"E3ISZ;1J16KT#Z]57P*%/I[BM?;?^NK/
MBO\`9=_X)_\`[,'[(=E&WPD\`6X\5-;_`&;4/B-XHD3Q#X^U)'7;.KZY=PJF
ME6MSRUQIGAVTT;2Y7+2/9-))([?:E%%?>X/!83`4(8;!8>EAL/#2%*C!0A'T
M2.24I3DY2;E)[R>K?S"BBBNHD****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
7`****`"BBB@`HHHH`****`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
